Ask Stago (english version)

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in hemostasis. 
In today episode, our expert guest, Laure Morimont, Project leader at QUALIblood SA, will detail with us the current knowledge on thrombotic risk under hormonal therapy and how this can be assessed.  

 As usual, don’t forget to send any question you may have to [email protected], we will be glad to answer to it. 

Learn more ⬇️
Literature sources: 

• de Bastos  M, Stegeman  BH, Rosendaal  FR, Van Hylckama Vlieg  A, Helmerhorst  FM, Stijnen  T, Dekkers  OM. Combined oral contraceptives: venous thrombosis. Cochrane Database of Systematic Reviews 2014, Issue 3. Art. No.: CD010813. DOI: 10.1002/14651858.CD010813.pub2. Accessed 16 June 2021. 
• Douxfils J, Morimont L, Bouvy C. Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk. Semin Thromb Hemost. 2020 Nov;46(8):872-886. doi: 10.1055/s-0040-1714140. Epub 2020 Oct 20. PMID: 33080636. 
• Abou-Ismail MY, Citla Sridhar D, Nayak L. Estrogen and thrombosis: A bench to bedside review. Thromb Res. 2020 Aug;192:40-51. doi: 10.1016/j.thromres.2020.05.008. Epub 2020 May 11. PMID: 32450447; PMCID: PMC7341440. 
• Morimont L, Dogné JM, Douxfils J. Letter to the Editors-in-Chief in response to the article of Abou-Ismail, et al. entitled "Estrogen and thrombosis: A bench to bedside review" (Thrombosis Research 192 (2020) 40-51). Thromb Res. 2020 Sep;193:221-223. doi: 10.1016/j.thromres.2020.08.006. Epub 2020 Aug 5. PMID: 32798963. 

Visit QUALIblood website: https://www.qualiblood.eu

Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice. 
 

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in haemostasis. 

In today episode, our co-host Cécile Hourquet, Product Line Manager for eSolutions and services, will come to talk about the digitalization of the laboratories.   

As usual, don’t forget to send any question you may have to [email protected], we will be glad to answer to it. 

Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice. 

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in coagulation. 

In today episode, Stephen MacDonald, Principal Clinical Scientist from Cambridge University Hospital, will demystify the process of Measurement Uncertainty determination.   

As usual, don’t forget to send any question you may have to [email protected], we will be glad to answer to it.  

To learn more: 

• Go on the websites
  •  👉 https://pathologyuncertainty.com/ 
  •   👉 https://www.pathologymu.com/ 
  •   👉 https://pathologymu.teachable.com/
• Follow there Twitter https://twitter.com/pathologyMU?

Literature: 

• ISO/TS 20914: 2019 Medical laboratories – Practical guidance for the estimation of measurement uncertainty.

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in haemostasis. 

In today episode, our expert Marisa Ninivaggi, research project leader at Synapse research institute, will explain us what is thrombin generation. 

As usual, don’t forget to send any question you may have to [email protected], we will be glad to answer to it. 

Learn more  👇
Literature sources: 

• Castoldi E, Rosing J. Thrombin generation tests. Thromb Res. 2011 Feb;127 Suppl 3:S21-5. doi: 10.1016/S0049-3848(11)70007-X 
• Baglin T. The measurement and application of thrombin generation. Br J Haematol. 2005 Sep;130(5):653-61. doi: 10.1111/j.1365-2141.2005.05612.x. 
• Hemker HC, Béguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost. 1995 Jul;74(1):134-8. Erratum in: Thromb Haemost 1995 Nov;74(5):1388. 
• Duarte RCF, Ferreira CN, Rios DRA, Reis HJD, Carvalho MDG. Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations. Rev Bras Hematol Hemoter. 2017;39(3):259-265. doi:10.1016/j.bjhh.2017.03.009 
• Al Dieri R, de Laat B, Hemker HC. Thrombin generation: what have we learned? Blood Rev. 2012 Sep;26(5):197-203. doi: 10.1016/j.blre.2012.06.001. 
• Hemker HC. Recollections on thrombin generation. J Thromb Haemost. 2008 Feb;6(2):219-26. doi: 10.1111/j.1538-7836.2007.02864.x. 
• Macfarlane, R. & Biggs, R. (1953) A thrombin generation test; the application in haemophilia and thrombocytopenia. Journal of Clinical Pathology, 6, 3–8 
• de Laat‐Kremers, RMW, Ninivaggi, M, Devreese, KMJ, de Laat, B. Towards standardization of thrombin generation assays: Inventory of thrombin generation methods based on results of an International Society of Thrombosis and Haemostasis Scientific Standardization Committee survey. J Thromb Haemost. 2020; 18: 1893– 1899. https://doi.org/10.1111/jth.14863
• Waters EK, Hilden I, Sørensen BB, Ezban M, Holm PK. Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive. J Thromb Haemost. 2015 Nov;13(11):2041-52. doi: 10.1111/jth.13134.. 
• Poitevin S, Cochery-Nouvellon E, Dupont A, Nguyen P. Monocyte IL-10 produced in response to lipopolysaccharide modulates thrombin generation by inhibiting tissue factor expression and release of active tissue factor-bound microparticles. Thromb Haemost. 2007 Apr;97(4):598-607. 
• Tripodi A. Usefulness of Thrombin Generation. Hamostaseologie. 2020 Nov;40(4):509-514. doi: 10.1055/a-1200-0417. 
• https://pubmed.ncbi.nlm.nih.gov/?term=thrombin+generation&sort=date accessed April 23, 2021 
• Marchetti M, Giaccherini C, Masci G, Verzeroli C, Russo L, Celio L, Sarmiento R, Gamba S, Tartari CJ, Diani E, Vignoli A, Malighetti P, Spinelli D, Kuderer NM, Nichetti F, Minelli M, Tondini C, Barni S, Giuliani F, Petrelli F, D'Alessio A, Gasparini G, Labianca R, Santoro A, De Braud F, Falanga A; HYPERCAN Investigators. Thrombin generation predicts early recurrence in breast cancer patients. J Thromb Haemost. 2020 Sep;18(9):2220-2231. doi: 10.1111/jth.14891  
• Gomez-Rosas P, Pesenti M, Verzeroli C et al Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence · TH Open 2021; 05(01): e56-e65 DOI: 10.1055/s-0040-1722609 
• Metze M, Pfrepper C, Klöter T, Stöbe S, Siegemund R, Siegemund T, Edel E, Laüfs U, Petros S,  Inhibition of thrombin generation 12 hours after intake of direct oral anticoagulant, Res Pract Thromb Haemost 2020  doi: 10.1002/rth2.12332   
• Douxfils J, Morimont L, Bouvy C. Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk. Semin Thromb Hemost. 2020 Nov;46(8):872-886. doi: 10.1055/s-0040-1714140. 
• Zermatten MG, Bertaggia Calderara D, Aliotta A, Alberio L, Thrombin generation in a woman with heterozygous factor V Leiden and combined oral contraceptives: A case report Res Pract Thromb Haemost  2020 doi: 10.1002/rth2.12318 
• Talon L, Sinegre T, Lecompte T, Pereira B, Massoulié S, Abergel A, Lebreton A, Hypercoagulability (thrombin generation) in patients with cirrhosis detected with ST Genesia, J Thromb Haemost 2020 doi: 10.1111/JTH.14963   
• Dargaud Y, Lienhart A, Janbain M, Le Quellec S, Enjolras N, Negrier C. Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab. Haematologica. 2018 Apr;103(4):e181-e183. doi: 10.3324/haematol.2017.185330.  
• Calzavarini S, Brodard J, Quarroz C, Maire L, Nützi R, Jankovic J, Rotondo LC, Fiedler GM, Nagler M, Angelillo-Scherrer A, Thrombin generation measurement using the ST Genesia Thrombin Generation System in a cohort of healthy adults: Normal values and variability, Res Pract Thromb Haemost 2019; 00: 1-11 doi: 10.1002/rth2.12238 
• Ninivaggi, M, de Laat‐Kremers, RMW, Carlo, A, de Laat, B. ST Genesia reference values of 117 healthy donors measured with STG‐BleedScreen, STG‐DrugScreen and STG‐ThromboScreen reagents. Res Pract Thromb Haemost. 2020; 00: 1– 10. https://doi.org/10.1002/rth2.12455
• Foulon-Pinto G, Jourdi G, Perrin J, Abdoul J, Paris G, Gouin-Thibault I, Curis E, Lecompte T, Siguret V. Study of thrombin generation with St Genesia to evaluate xaban  pharmacodynamics: Analytical performances over 18 months. Int J Lab Hematol. 2020 Dec 28. doi: 10.1111/ijlh.13443 
• Tripodi A. Thrombin Generation Assay and Its Application in the Clinical Laboratory. Clin Chem. 2016 May;62(5):699-707. doi: 10.1373/clinchem.2015.248625. 

____________________________________________________________________________________________________________

Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice. 

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in haemostasis. 

In today episode, our expert Rachael Lamma, a member of our US technical support specialist team, will explain how to handle lot conversion in the daily laboratory organization.  

As usual, don’t forget to send any question you may have to [email protected], we will be glad to answer to it.

Learn more 👇 
Literature sources: 

• College of American Pathologists. All Common Checklist. Northfield, IL: College of American Pathologists; 2020 
• CLSI. User Evaluation of Between-Reagent Lot Variation; Approved Guideline. CLSI Document P26-A. Wayne PA: Clinical and Laboratory Standard Institute; 2013 

___________________________________________________________________________________________________________

Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice. 

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. 

In today’s episode, our expert our expert François Depasse, Clinical development Director, will help us to clarify when thrombophilia testing is appropriate and how to perform it according to international standards.  

As usual, don’t forget to send any question you may have to [email protected] we will be glad to answer to it. 

Literature sources: 

• https://www.cochranelibrary.com/advanced-search/mesh;jsessionid=DED8CB403679070FD38E81E38E5A7ECA accessed March 17, 2021 
• Montagnana M, Lippi G, Danese E. An Overview of Thrombophilia and Associated Laboratory Testing. Methods Mol Biol. 2017;1646:113-135. doi: 10.1007/978-1-4939-7196-1_9. 
• Merriman L, Greaves M. Testing for thrombophilia: an evidence-based approach. Postgrad Med J. 2006 Nov;82(973):699-704. doi: 10.1136/pgmj.2006.048090.  
• Gruel Y et al, Thrombophilia testing: Proposals of the 2020 GFHT. Rev Francoph Hémost Thromb 2020 ; 2 (3) : 93-126 
• Delluc A, Antic D, Lecumberri R, Ay C, Meyer G, Carrier M. Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2017 Oct;15(10):2076-2079. doi: 10.1111/jth.13791. Epub 2017 Aug 29. Erratum in: J Thromb Haemost. 2017 Dec;15(12 ):2471. 
• D'Astous J, Carrier M. Screening for Occult Cancer in Patients with Venous Thromboembolism. J Clin Med. 2020 Jul 27;9(8):2389. doi: 10.3390/jcm9082389 
• Connors JM. Thrombophilia Testing and Venous Thrombosis. N Engl J Med. 2017 Sep 21;377(12):1177-1187. doi: 10.1056/NEJMra1700365. 
• National Institute for Health and Care Excellence. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. NG 158, London 2020 
• De Stefano V, Rossi E. Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the Guidelines from Scientific Societies and Working Groups. Thromb Haemost. 2013 Oct;110(4):697-705. doi: 10.1160/TH13-01-0011. 
• Moll, S. Who should be tested for thrombophilia?. Genet Med 13, 19–20 (2011). 
• Cooper PC, Pavlova A, Moore GW, Hickey KP, Marlar RA. Recommendations for clinical laboratory testing for protein C deficiency, for the subcommittee on plasma coagulation inhibitors of the ISTH. J Thromb Haemost. 2020 Feb;18(2):271-277. doi: 10.1111/jth.14667.  
• Marlar RA, Gausman JN, Tsuda H, Rollins-Raval MA, Brinkman HJM. Recommendations for clinical laboratory testing for protein S deficiency: Communication from the SSC committee plasma coagulation inhibitors of the ISTH. J Thromb Haemost. 2021 Jan;19(1):68-74. doi: 10.1111/jth.15109. 
• Van Cott EM, Orlando C, Moore GW, Cooper PC, Meijer P, Marlar R; Subcommittee on Plasma Coagulation Inhibitors. Recommendations for clinical laboratory testing for antithrombin deficiency; Communication from the SSC of the ISTH. J Thromb Haemost. 2020 Jan;18(1):17-22.  
• Devreese KMJ, de Groot PG, de Laat B, Erkan D, Favaloro EJ, Mackie I, Martinuzzo M, Ortel TL, Pengo V, Rand JH, Tripodi A, Wahl D, Cohen H. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost. 2020 Nov;18(11):2828-2839. doi: 10.1111/jth.15047. 
• Sevenet PO, Cucini V, Hervé T, Depasse F, Carlo A, Contant G, Mathieu O. Evaluation of DOAC Filter, a new device to remove direct oral anticoagulants from plasma samples. Int J Lab Hematol. 2020 Oct;42(5):636-642. doi: 10.1111/ijlh.13267. 
• Exner T, Michalopoulos N, Pearce J, Xavier R, Ahuja M. Simple method for removing DOACs from plasma samples. Thromb Res. 2018;163:117-122 

Related podcasts:  

• S1E13 - The Lupus Anticoagulant Diagnosis Work up - https://www.podcastics.com/episode/54015/link/

  https://www.podcastics.com/episode/54015/link/

____________________________________________________________________________________________________________

Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice. 

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. 

In today’s episode, our expert Paul, in honor of the upcoming World Hemophilia Day, taking place April 17, will return to our podcast series to cover clinical laboratory testing approaches for patients with inherited or acquired haemophilia.  

Literature sources: 

• Iorio A, Stonebraker JS, Chambost H, Makris M, Coffin D, Herr C, et al.; Data and Demographics Committee of the World Federation of Hemophilia. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. Ann Intern Med. 2019 Oct 15;171(8):540-546.  
• Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al.; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020 Aug;26 Suppl 6:1-158.  
• College of American Pathologists. Hematology and Coagulation Checklist. Northfield, IL: College of American Pathologists; 2020. 

Related podcasts:  

• S2E4 – how to determine factor levels in hemophilia - https://www.podcastics.com/episode/62593/link/ 

____________________________________________________________________________________________________________

Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice. 

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. In today episode, our expert Thomas, is covering with us the usages of APTT testing.  

Literature sources: 

• Toulon, P., Eloit, Y., Smahi, M., Sigaud, C., Jambou, D., Fischer, F. and Appert‐Flory, A. (2016), In vitro sensitivity of different activated partial thromboplastin time reagents to mild clotting factor deficiencies. Int. Jnl. Lab. Hem., 38: 389-396. https://doi.org/10.1111/ijlh.12499
• CLSI One-stage Prothrombin Time (PT) test and Activated Partial Thromboplastin Time (APTT) test; Approved guideline - second edition. CLSI document H47-A2 Wayne, PA: Clinical and Laboratory Standard Institute, 2008 
• Levy JH, Szlam F, Wolberg AS, Winkler A. Clinical use of the activated partial thromboplastin time and prothrombin time for screening: a review of the literature and current guidelines for testing. Clin Lab Med. 2014 Sep;34(3):453-77. doi: 10.1016/j.cll.2014.06.005 
• Kitchen S, Jennings I, Woods TA, Preston FE. Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol. 1996 Jan;49(1):10-4. doi: 10.1136/jcp.49.1.10. 
• Gosselin RC, King JH, Janatpour KA, Dager WE, Larkin EC, Owings JT. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. Ann Pharmacother. 2004 Sep;38(9):1383-8. doi: 10.1345/aph.1D565. 
• Gouin-Thibaut I, Martin-Toutain I, Peynaud-Debayle E, et al. Monitoring unfractionated heparin with APTT: a French collaborative study comparing sensitivity to heparin of 15 APTT reagents. Thrombosis Research. 2012 May;129(5):666-667. DOI: 10.1016/j.thromres.2011.11.016. 
• Triplett DA. Screening for the lupus anticoagulant. Ricerca in Clinica E in Laboratorio. 1989; 19-379-89 
• Denis-Magdelaine A et al; Sensitivity of sixteen APTT reagents for the presence of anticoagulant. Haemostasis 1995; 25:98-105/ 
• Rozen L, Copette F, Noubouossie DF, Demulder A. Evaluation of three APTT reagents in a routine laboratory: toward a compromise. Clin Lab. 2013;59(7-8):921-4. doi: 10.7754/clin.lab.2012.120909 
• van Rossum, A.P., Vlasveld, L.T., van den Hoven, L.J.M., de Wit, C.W.M. and Castel, A. (2012), False prolongation of the activated partial thromboplastin time (aPTT) in inflammatory patients: interference of C‐reactive protein. Br J Haematol, 157: 394-395. https://doi.org/10.1111/j.1365-2141.2011.08990.x 
• Gu, J.‐M., Ramsey, P., Evans, V., Tang, L., Apeler, H., Leong, L., Murphy, J.E., Laux, V. and Myles, T. (2014), Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94‐9027) for haemophilia A. Haemophilia, 20: 593-600. https://doi.org/10.1111/hae.12374
• Hillarp A, Bowyer A, Ezban M, Persson P, Kitchen S. Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study. Haemophilia. 2017 May;23(3):458-465. doi: 10.1111/hae.13168. 
• Ezban M, Hansen M, Kjalke M. An overview of turoctocog alfa pegol (N8-GP; ESPEROCT® ) assay performance: Implications for postadministration monitoring. Haemophilia. 2020;26(1):156-163. doi:10.1111/hae.13897 

Related podcasts: 

• Ask Stago S1E11: UFH monitoring: APTT or Anti-Xa? https://www.podcastics.com/podcast/episode/11-%E2%80%93-monitoring-of-ufh-aptt-or-anti-xa-41033/ 
• Ask Stago S1E13: The Lupus Anticoagulant Diagnosis work up: https://www.podcastics.com/podcast/episode/13-the-lupus-anticoagulant-diagnosis-work-up -54015/

____________________________________________________________________________________________________________

Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice. 

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in hemostasis. 

In today episode, our expert Pierre Bourgeat, will discuss about the Prothrombin time reagent characteristics with a specific focus on the ISI and the type of activators.  

As usual, don’t forget to send any question you may have to [email protected], we will be glad to answer to it.  

To learn more:

• Listen to our podcast about MNPT determination: #7 How to determine the mean normal prothrombin time 
• View the Webinar of Ian Jenning on stagowebinar.com  

Literature:

• Lusher, J. Screening and diagnosis of coagulation disorders. Am. J. Obstet. Gynecol. 1986; 175:778-783  
• Riley, R., Rowe, D., & Fisher, L. Clinical utilization of the international normalized ratio (INR). J. Clin. Lab. Anal. 2000; 14:101-114  
• WHO Technical Report Series, No. 610, 1977 
• Ian Jennings, PT/INR measurement for the management of VKA therapy, Stagowebinar.com, 3 October 2017 
• WHO Technical Report Series, No. 979, 2013 
• CLSI One-stage Prothrombin Time (PT) test and Activated Partial Thromboplastin Time (APTT) test; Approved guideline - second edition. CLSI document H47-A2 Wayne, PA: Clinical and Laboratory Standard Institute, 2008 
• Smith SA, Comp PC, Morrissey JH. Traces of factor VIIa modulate thromboplastin sensitivity to factors V, VII, X, and prothrombin. J Thromb Haemost. 2006;4(7):1553-1558. 

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.